Tech Center 1600 • Art Units: 1682
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17747603 | MULTI-OMIC ANALYSIS OF EXTRACELLULAR VESICLES IN MONODISPERSE DROPLETS | Non-Final OA | ILLUMINA, INC. |
| 18152042 | METHODS OF DETECTING GENOMIC REARRANGEMENTS USING CELL FREE NUCLEIC ACIDS | Final Rejection | GUARDANT HEALTH, INC. |
| 18266085 | SPATIAL GENOMICS WITH SINGLE CELL RESOLUTION | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17881086 | ANALYTE CAPTURE FROM AN EMBEDDED BIOLOGICAL SAMPLE | Final Rejection | 10x Genomics, Inc. |
| 17506804 | NUCLEIC ACID DETECTION SYSTEM AND NUCLEIC ACID DETECTION METHOD | Final Rejection | CANON MEDICAL SYSTEMS CORPORATION |
| 18289455 | METHODS FOR DETECTING DYSFUNCTIONAL NK CELLS IN LEUKEMIA PATIENTS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18265571 | GENE SIGNATURE AND PREDICTION OF LUNG CANCER RESPONSE TO ADJUVANT CHEMOTHERAPY | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18284131 | METHODS OF DETERMINING TREATMENT OUTCOME | Non-Final OA | The Johns Hopkins University |
| 18268893 | DETECTION OF LUNG CANCER USING CELL-FREE DNA FRAGMENTATION | Non-Final OA | The Johns Hopkins University |
| 18570006 | METHODS OF USING SOMATIC HLA-I LOH TO PREDICT RESPONSE OF IMMUNE CHECKPOINT INHIBITOR-TREATED PATIENTS WITH LUNG CANCER | Non-Final OA | Foundation Medicine, Inc. |
| 18280513 | EPIGENETIC QUANTIFICATION USING DNA HYBRIDIZATION-BASED SINGLE-MOLECULE IMMUNOFLUORESCENT IMAGING | Non-Final OA | University of Cincinnati |
| 17948760 | THORACIC DUCT AS A SAMPLE COLLECTION RESERVOIR | Final Rejection | Washington University |
| 17929062 | ASSESSMENT OF MELANOMA THERAPY RESPONSE | Final Rejection | UNIVERSITY OF UTAH RESEARCH FOUNDATION |
| 17986357 | SEQUENCING OF DNA BY SEQUENTIAL ADDITION/INCORPORATION OF 3` UNPROTECTED LABELED NUCLEOTIDES | Final Rejection | Miltenyi Biotec B.V. & Co. KG |
| 18012607 | SPATIAL ANALYSIS OF MULTIPLE TARGETS IN TISSUE SAMPLES | Non-Final OA | ROCHE SEQUENCING SOLUTIONS, INC. |
| 17797950 | A METHOD OF DETERMINING A STRUCTURE OF RIBONUCLEIC ACID MOLECULES AND RELATED KITS | Final Rejection | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH |
| 17300940 | Molecular Barcode Analysis by Single-Molecule Kinetics | Non-Final OA | Quantum-Si Incorporated |
| 17436496 | COMPOSITIONS AND METHODS OF LABELING NUCLEIC ACIDS AND SEQUENCING AND ANALYSIS THEREOF | Final Rejection | King Abdullah University of Science and Technology |
| 18036392 | SINGLE-CELL PROFILING OF CHROMATIN OCCUPANCY AND RNA SEQUENCING | Non-Final OA | The United States of America, as represented by the Secretary, Dept. of Health and Human Services |
| 17763002 | PROBE AND METHOD FOR STR-GENOTYPING | Final Rejection | Universiteit Gent |
| 18316454 | USE OF UNIQUE MOLECULAR IDENTIFIERS FOR IMPROVED ACCURACY OF LONG READ SEQUENCING AND CHARACTERIZATION OF CRISPR EDITING | Non-Final OA | INTEGRATED DNA TECHNOLOGIES, INC. |
| 18286081 | METHOD OF DETECTING CANCER USING GENOME-WIDE CFDNA FRAGMENTATION PROFILES | Non-Final OA | Delfi Diagnostics, Inc. |
| 17776741 | METHOD FOR DETECTING OR QUANTIFYING OLIGONUCLEOTIDE | Final Rejection | SEKISUI MEDICAL CO., LTD. |
| 17920597 | NUCLEIC ACID DETECTION METHOD AND OLIGONUCLEOTIDE PROBE | Non-Final OA | NICCA CHEMICAL CO., LTD. |
| 17625308 | APTAMER FOR TGF-BETA1 AND USE OF SAME | Non-Final OA | RIBOMIC INC. |
| 18062918 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID ANALYSIS | Non-Final OA | LUMINEX CORPORATION |
| 17643161 | METHODS AND KITS FOR DETECTING SPERM DNA FRAGMENTATION | Final Rejection | Bonraybio Co., Ltd. |
| 17758656 | METHODS OF TARGETED SEQUENCING | Final Rejection | JUMPCODE GENOMICS, INC. |
| 17756610 | Detecting Congenital Heart Defect | Final Rejection | Bioscreening & Diagnostics LLC |
| 17630304 | MOLECULAR CLASSIFIERS FOR PROSTATE CANCER | Non-Final OA | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy